Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eli Lilly and Company's Cymbalta (duloxetine Hcl) has received approval from the US Food and Drug Administration (FDA) for the management of chronic musculoskeletal pain.
Subscribe to our email newsletter
Cymbalta has been established in studies in patients with chronic low back pain and chronic pain due to osteoarthritis.
Cymbalta, which has been shown to reduce chronic low back pain and chronic pain due to osteoarthritis, is a non-narcotic pain reliever that is meant to be taken once a day, every day by people with these pain conditions, Lilly said.
Lilly said that although the exact way that Cymbalta works to reduce chronic musculoskeletal pain is unknown, it is believed that Cymbalta helps lessen pain by enhancing the body’s natural pain suppressing system by increasing the activity of serotonin and norepinephrine in the brain and spinal cord.
The Johns Hopkins Medical Institutions Chronic Pain Treatment Program Department of Psychiatry and Behavioral Sciences director Michael Clark said that the approval of Cymbalta for chronic musculoskeletal pain by the FDA gives doctors another option to help an underserved and suffering group of patients.
American Chronic Pain Association executive director Penney Cowan said that having a medication that is approved specifically for people with chronic musculoskeletal pain is a great step in helping these individuals live with less chronic low back pain or chronic pain due to osteoarthritis.